Anavex up 12% premarket on Fast Track of lead candidate for Rett syndrome

Anavex Life Sciences (NASDAQ:AVXL) is up 12% premarket on average volume in response to its announcement that the FDA has designated AVAVEX 2-73 (blarcamesine) for Fast Track review for the treatment of Rett syndrome, a rare inherited neurological disorder occurring primarily in girls.

Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.

Phase 2 studies (AVATAR and 001) are ongoing.

https://seekingalpha.com/news/3537211-anavex-up-12-premarket-on-fast-track-of-lead-candidate-for-rett-syndrome